Aperio Group’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $112M | Buy |
1,183,853
+62,090
| +6% | +$5.43M | 0.33% | 52 |
|
|
2020
Q3 | $97.5M | Sell |
1,121,763
-84,283
| -7% | -$7.3M | 0.33% | 53 |
|
|
2020
Q2 | $105M | Buy |
1,206,046
+58,049
| +5% | +$5.01M | 0.39% | 46 |
|
|
2020
Q1 | $94.7M | Sell |
1,147,997
-34,479
| -3% | -$3.08M | 0.42% | 43 |
|
|
2019
Q4 | $112M | Sell |
1,182,476
-52,814
| -4% | -$4.74M | 0.4% | 43 |
|
|
2019
Q3 | $107M | Buy |
1,235,290
+49,902
| +4% | +$4.48M | 0.42% | 41 |
|
|
2019
Q2 | $108M | Sell |
1,185,388
-48,719
| -4% | -$4.12M | 0.44% | 39 |
|
|
2019
Q1 | $106M | Buy |
1,234,107
+3,862
| +0.3% | +$310K | 0.46% | 34 |
|
|
2018
Q4 | $94.6M | Buy |
1,230,245
+153,892
| +14% | +$12M | 0.48% | 33 |
|
|
2018
Q3 | $83.1M | Buy |
1,076,353
+118,921
| +12% | +$8.79M | 0.37% | 50 |
|
|
2018
Q2 | $64.8M | Sell |
957,432
-69,145
| -7% | -$4.77M | 0.31% | 59 |
|
|
2018
Q1 | $74.4M | Buy |
1,026,577
+23,537
| +2% | +$1.79M | 0.37% | 48 |
|
|
2017
Q4 | $75.5M | Buy |
1,003,040
+87,706
| +10% | +$6.62M | 0.38% | 45 |
|
|
2017
Q3 | $70.4M | Buy |
915,334
+69,980
| +8% | +$5.29M | 0.4% | 47 |
|
|
2017
Q2 | $63.2M | Buy |
845,354
+67,822
| +9% | +$4.81M | 0.39% | 42 |
|
|
2017
Q1 | $51.7M | Buy |
777,532
+66,916
| +9% | +$4.46M | 0.35% | 48 |
|
|
2016
Q4 | $46.4M | Sell |
710,616
-431,774
| -38% | -$28M | 0.35% | 47 |
|
|
2016
Q3 | $80.8M | Buy |
1,142,390
+56,932
| +5% | +$4.15M | 0.59% | 23 |
|
|
2016
Q2 | $80.3M | Buy |
1,085,458
+233,768
| +27% | +$16.2M | 0.63% | 23 |
|
|
2016
Q1 | $55.3M | Sell |
851,690
-110,270
| -11% | -$7.5M | 0.47% | 37 |
|
|
2015
Q4 | $74.2M | Buy |
961,960
+33,277
| +4% | +$2.64M | 0.68% | 16 |
|
|
2015
Q3 | $76.5M | Buy |
928,683
+33,437
| +4% | +$2.98M | 0.78% | 12 |
|
|
2015
Q2 | $78.9M | Buy |
895,246
+37,520
| +4% | +$3.44M | 0.81% | 9 |
|
|
2015
Q1 | $75.8M | Buy |
857,726
+60,616
| +8% | +$5.38M | 0.85% | 9 |
|
|
2014
Q4 | $66.2M | Buy |
797,110
+49,500
| +7% | +$4.1M | 0.82% | 10 |
|
|
2014
Q3 | $63.1M | Buy |
747,610
+58,689
| +9% | +$4.75M | 0.85% | 9 |
|
|
2014
Q2 | $55.9M | Buy |
688,921
+88,153
| +15% | +$6.93M | 0.81% | 10 |
|
|
2014
Q1 | $45.8M | Buy |
+600,768
| New | +$43.8M | 0.64% | 13 |
|
|
2013
Q4 | – | Sell |
-432,086
| Closed | -$30M | – | 16 |
|
|
2013
Q3 | $29.7M | Buy |
432,086
+76,184
| +21% | +$5.04M | 0.57% | 17 |
|
|
2013
Q2 | $22.6M | Buy |
+355,902
| New | +$23.2M | 0.54% | 23 |
|
Other funds holding NVS
Aperio Group's NVS Position: Q4 2020 in Review
Aperio Group increased its Novartis (NVS) stake by 5.5% in Q4 2020, buying an estimated $5.43M and bringing the position to 1,183,853 shares worth $112M. The position accounts for 0.33% of the portfolio, ranked #52.
Aperio Group first reported a position in NVS in Q2 2013 and has held it in 30 quarters since. The position peaked at $112M in Q4 2019. 1,177 funds tracked by Wall St. Rank hold NVS as of Q4 2020.
- Aperio Group held 1,183,853 shares of Novartis worth $112M as of Q4 2020.
- Aperio Group bought 62,090 Novartis shares in Q4 2020, an estimated $5.43M.
- Novartis made up 0.33% of Aperio Group's portfolio in Q4 2020, its #52 holding.
- Aperio Group first reported a position in Novartis in Q2 2013 and has held it in 30 quarters since.
- Aperio Group's Novartis position peaked at $112M in Q4 2019.
- 1,177 funds tracked by Wall St. Rank held Novartis as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.